Industry news · Business & finance← The news desk

✦ The Dispatch

New AI platform and Asia push to keep Sonova ahead of Demant: “We will continue to take share”

A dispatch from MedWatch — filed

Middle-aged man with short grey hair and black-rimmed glasses in a white shirt, gesturing while speaking at a conference table
✦ PlateMiddle-aged man with short grey hair and black-rimmed glasses in a white shirt, gesturing while speaking at a conference table

CEO Eric Bernard sees Sonova leading the race against Demant and is betting on a new platform and Asia. Growth in cochlear implants, however, now clearly depends on FDA approval.

Continue reading at MedWatch

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

No actionable change — this is a corporate strategy interview with no clinical evidence or guidance implications for practicing audiologists.

✦ Why It Matters ✦

Sonova's declared AI platform investment and Asia expansion signal a likely acceleration in AI-driven hearing aid features and increased global market competition, which could shape product availability and pricing for clinics worldwide.

✦ Key Points ✦
  1. 01Sonova CEO Eric Bernard signals intent to outgrow Demant via a new AI platform and Asia-Pacific expansion.
  2. 02Cochlear implant growth is explicitly tied to pending FDA regulatory approval.
  3. 03AI integration is positioned as a core competitive differentiator against rival manufacturers.
  4. 04Asia is identified as a key untapped market for hearing technology growth.
  5. 05The statement 'we will continue to take share' reflects a confident, competitive posture — not confirmed market data.
✦ Claims & Evidence ✦

Sonova will continue to take market share from competitors, including Demant.

quoteunclear

Sonova's cochlear implant growth depends on FDA approval.

quotesupported

A new AI platform will help Sonova outpace Demant.

quotepromotional
✦ Related stories ✦